OpenNashPodcasts

Person

Andrew von Eschenbach

Andrew von Eschenbach is a former FDA Commissioner who appeared on Mike Milken's podcast, Conversations with Mike Milken, to discuss the coronavirus response, drug supply chains and the history of cancer research funding.

In 2020, he said cell-based methods could cut vaccine production from the usual year to 18 months down to six months or less. He also said the FDA approved trials using the body's immune system against the virus. He described how, while he led the FDA, the agency created its "Beyond Our Borders" program, with offices in China, India, Europe, Central America and later the Middle East. He also credited Mike Milken with pushing for larger cancer and health research funding.

1 episodes · 11 quoted claims

Andrew von Eschenbach says modern cell-based methods could cut vaccine production from the normal year to 18 months down to six months or less.

“not take the normal year to 18 months, but to cut that immediately down to six months or less.”

Conversations with Mike Milken · 0:05:23

Andrew von Eschenbach says monoclonal antibodies could be developed from antibodies made by people who have recovered from the coronavirus.

“develop monoclonal antibodies by finding people who have conquered the virus, have already made an antibody within their own system to destroy or fight off that virus.”

Conversations with Mike Milken · 0:06:27

Andrew von Eschenbach says the FDA approved clinical trials using the body's immune system, including natural killer cells, against the coronavirus.

“FDA has approved clinical trials to use our own body's immune system, including using natural killer cells that are already in our body.”

Conversations with Mike Milken · 0:08:11

Andrew von Eschenbach says hydroxychloroquine was already used for malaria, rheumatoid arthritis and lupus before it was used against COVID-19.

“hydroxychloroquine, which was used for malaria and rheumatoid arthritis and lupus”

Conversations with Mike Milken · 0:08:45

Andrew von Eschenbach says real-world patient data must be acquired, aggregated and analyzed to learn how off-the-shelf drugs work against COVID-19.

“we'll have to capitalize on the opportunity to acquire, aggregate, and analyze real-world data”

Conversations with Mike Milken · 0:10:09

Andrew von Eschenbach says existing electronic medical record systems should be used, with patient permission, to capture COVID-19 treatment data.

“We need to capitalize on the healthcare systems that are already in place based on an electronic medical record, recruit and utilize them with patient's permission to be able to get access to that data.”

Conversations with Mike Milken · 0:11:03

Andrew von Eschenbach says spending hundreds of millions on a vaccine candidate that proves not to be the best would still be a worthwhile investment.

“It may very well be that we'll develop a vaccine and spend a considerable amount of money, hundreds of millions perhaps, and it may not be the absolute best vaccine in the long run.”

Conversations with Mike Milken · 0:11:40

Andrew von Eschenbach says that while he led the FDA, much production of drug ingredients, excipients and gelatin capsules took place outside the United States.

“the production of, for example, active pharmaceutical ingredients and excipients, even the gelatin that you find your medicines encapsulated in, and many other things were occurring and being developed outside the United States.”

Conversations with Mike Milken · 0:13:54

Under Andrew von Eschenbach, the FDA created its 'Beyond Our Borders' program and placed personnel and offices in China, India, Europe, Central America and later the Middle East.

“we created FDA Beyond Our Borders and actually put FDA personnel and offices in China, in India, in Europe, in Central America, and eventually in the Middle East.”

Conversations with Mike Milken · 0:14:35

Andrew von Eschenbach says Mike Milken advocated for dramatic funding increases at the National Cancer Institute and the National Institutes of Health.

“You not only advocated for dramatic increases in funding at the National Cancer Institute and the NIH”

Conversations with Mike Milken · 0:07:02

Andrew von Eschenbach says Mike Milken pushed the academic and scientific community to collaborate and break down silos, helping create an era of molecular medicine.

“And what you did was force us to collaborate and cooperate, to break down silos.”

Conversations with Mike Milken · 0:07:02